Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer
This article is part of Special Issue:
Lior Z. Braunstein,
Ming-Hui Chen,
Marian Loffredo,
Philip W. Kantoff,
Anthony V. D′Amico,
Corresponding Author
Lior Z. Braunstein
Harvard Radiation Oncology Program, Brigham and Women’s Hospital, ASB-I Radiation Oncology L2, 75 Francis Street, Boston, MA 02115, USA
Search for more papers by this authorMing-Hui Chen
Department of Statistics, University of Connecticut, 215 Glenbrook Road, U-4120 , Storrs, CT 06269-4120, USA uconn.edu
Search for more papers by this authorMarian Loffredo
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Mailstop Dana 1230, 450 Brookline Avenue, Boston, MA 02215, USA dana-farber.org
Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Hospital, ASB-I Radiation Oncology L2, 75 Francis Street, Boston, MA 02115, USA
Search for more papers by this authorPhilip W. Kantoff
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Mailstop Dana 1230, 450 Brookline Avenue, Boston, MA 02215, USA dana-farber.org
Search for more papers by this authorAnthony V. D′Amico
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Mailstop Dana 1230, 450 Brookline Avenue, Boston, MA 02215, USA dana-farber.org
Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Hospital, ASB-I Radiation Oncology L2, 75 Francis Street, Boston, MA 02115, USA
Search for more papers by this authorLior Z. Braunstein,
Ming-Hui Chen,
Marian Loffredo,
Philip W. Kantoff,
Anthony V. D′Amico,
Corresponding Author
Lior Z. Braunstein
Harvard Radiation Oncology Program, Brigham and Women’s Hospital, ASB-I Radiation Oncology L2, 75 Francis Street, Boston, MA 02115, USA
Search for more papers by this authorMing-Hui Chen
Department of Statistics, University of Connecticut, 215 Glenbrook Road, U-4120 , Storrs, CT 06269-4120, USA uconn.edu
Search for more papers by this authorMarian Loffredo
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Mailstop Dana 1230, 450 Brookline Avenue, Boston, MA 02215, USA dana-farber.org
Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Hospital, ASB-I Radiation Oncology L2, 75 Francis Street, Boston, MA 02115, USA
Search for more papers by this authorPhilip W. Kantoff
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Mailstop Dana 1230, 450 Brookline Avenue, Boston, MA 02215, USA dana-farber.org
Search for more papers by this authorAnthony V. D′Amico
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Mailstop Dana 1230, 450 Brookline Avenue, Boston, MA 02215, USA dana-farber.org
Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Hospital, ASB-I Radiation Oncology L2, 75 Francis Street, Boston, MA 02115, USA
Search for more papers by this authorAcademic Editor: Manfred Wirth
Abstract
Background. Increasing body mass index (BMI) is associated with increased risk of mortality; however, quantifying weight gain in men undergoing androgen deprivation therapy (ADT) for prostate cancer (PC) remains unexplored. Methods. Between 1995 and 2001, 206 men were enrolled in a randomized trial evaluating the survival difference of adding 6 months of ADT to radiation therapy (RT). BMI measurements were available in 171 men comprising the study cohort. The primary endpoint was weight gain of ≥10 lbs by 6-month followup. Logistic regression analysis was performed to assess whether baseline BMI or treatment received was associated with this endpoint adjusting for known prognostic factors. Results. By the 6-month followup, 12 men gained ≥10 lbs, of which 10 (83%) received RT + ADT and, of these, 7 (70%) were obese at randomization. Men treated with RT as compared to RT + ADT were less likely to gain ≥10 lbs (adjusted odds ratio (AOR): 0.18 [95% CI: 0.04–0.89]; P = 0.04), whereas this risk increased with increasing BMI (AOR: 1.15 [95% CI: 1.01–1.31]; P = 0.04). Conclusions. Consideration should be given to avoid ADT in obese men with low- or favorable-intermediate risk PC where improved cancer control has not been observed, but shortened life expectancy from weight gain is expected.
References
- 1 Bolla M., Van Tienhoven G., De Reijke T., van den Bergh A., van der Meijden A., Poortmans P. et al., Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT—results of the randomized EORTC phase III trial 22961, Journal of Clinical Oncology. (2007) 25, no. supplement 18.
- 2 Bolla M., Van Tienhoven G., Warde P., Dubois J. B., Mirimanoff R.-O., Storme G., Bernier J., Kuten A., Sternberg C., Billiet I., Torecilla J. L., Pfeffer R., Cutajar C. L., Van der Kwast T., and Collette L., External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study, The Lancet Oncology. (2010) 11, no. 11, 1066–1073, 2-s2.0-78049527402, https://doi.org/10.1016/S1470-2045(10)70223-0.
- 3 D′Amico A. V., Manola J., Loffredo M., Renshaw A. A., DellaCroce A., and Kantoff P. W., 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial, Journal of the American Medical Association. (2004) 292, no. 7, 821–827, 2-s2.0-4043153049, https://doi.org/10.1001/jama.292.7.821.
- 4 Horwitz E. M., Bae K., Hanks G. E., Porter A., Grignon D. J., Brereton H. D., Venkatesan V., Lawton C. A., Rosenthal S. A., Sandler H. M., and Shipley W. U., Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer, Journal of Clinical Oncology. (2008) 26, no. 15, 2497–2504, 2-s2.0-45149105820, https://doi.org/10.1200/JCO.2007.14.9021.
- 5 Jones C. U., Hunt D., McGowan D. G., Amin M. B., Chetner M. P., Bruner D. W., Leibenhaut M. H., Husain S. M., Rotman M., Souhami L., Sandler H. M., and Shipley W. U., Radiotherapy and short-term androgen deprivation for localized prostate cancer, The New England Journal of Medicine. (2011) 365, no. 2, 107–118, 2-s2.0-79960227242, https://doi.org/10.1056/NEJMoa1012348.
- 6
Pilepich M. V.,
Winter K.,
John M. J.,
Mesic J. B.,
Sause W.,
Rubin P.,
Lawton C.,
Machtay M., and
Grignon D., Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate, International Journal of Radiation Oncology Biology Physics. (2001) 50, no. 5, 1243–1252, 2-s2.0-0035424063, https://doi.org/10.1016/S0360-3016(01)01579-6.
10.1016/S0360-3016(01)01579-6 Google Scholar
- 7 Pilepich M. V., Winter K., Lawton C. A., Krisch R. E., Wolkov H. B., Movsas B., Hug E. B., Asbell S. O., and Grignon D., Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31, International Journal of Radiation Oncology Biology Physics. (2005) 61, no. 5, 1285–1290, 2-s2.0-16344385883, https://doi.org/10.1016/j.ijrobp.2004.08.047.
- 8 Guise T. A., Oefelein M. G., Eastham J. A., Cookson M. S., Higano C. S., and Smith M. R., Estrogenic side effects of androgen deprivation therapy, Reviews in Urology. (2007) 9, no. 4, 163–180.
- 9 Holzbeierlein J. M., McLaughlin M. D., and Thrasher J. B., Complications of androgen deprivation therapy for prostate cancer, Current Opinion in Urology. (2004) 14, no. 3, 177–183, 2-s2.0-2342626087, https://doi.org/10.1097/00042307-200405000-00007.
- 10
Higano C. S., Side effects of androgen deprivation therapy: monitoring and minimizing toxicity, Urology. (2003) 61, no. 2, 32–38, 2-s2.0-0037299782, https://doi.org/10.1016/S0090-4295(02)02397-X.
10.1016/S0090‐4295(02)02397‐X Google Scholar
- 11 SmithJ. A.Jr., A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate, Journal of Urology. (1994) 152, no. 1, 132–134, 2-s2.0-0028236833.
- 12 Thompson C. A., Shanafelt T. D., and Loprinzi C. L., Andropause: symptom management for prostate cancer patients treated with hormonal ablation, Oncologist. (2003) 8, no. 5, 474–487, 2-s2.0-0141957526, https://doi.org/10.1634/theoncologist.8-5-474.
- 13 Chen A. C. and Petrylak D. P., Complications of androgen deprivation therapy in men with prostate cancer, Current Oncology Reports. (2004) 6, no. 3, 209–215, 2-s2.0-5444250665.
- 14 Smith M. R., Finkelstein J. S., McGovern F. J., Zietman A. L., Fallon M. A., Schoenfeld D. A., and Kantoff P. W., Changes in body composition during androgen deprivation therapy for prostate cancer, Journal of Clinical Endocrinology and Metabolism. (2002) 87, no. 2, 599–603, 2-s2.0-0036173823, https://doi.org/10.1210/jc.87.2.599.
- 15 Diamond T. H., Higano C. S., Smith M. R., Guise T. A., and Singer F. R., Osteoporosis in men with prostate carcinoma receiving androgen, deprivation therapy, Cancer. (2004) 100, no. 5, 892–899, 2-s2.0-1242336807, https://doi.org/10.1002/cncr.20056.
- 16 Berruti A., Dogliotti L., Terrone C., Cerutti S., Isaia G., Tarabuzzi R., Reimondo G., Mari M., Ardissone P., De Luca S., Fasolis G., Fontana D., Rossetti S. R., and Angeli A., Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy, Journal of Urology. (2002) 167, no. 6, 2361–2367, 2-s2.0-0036096151.
- 17 Haffner S. M., Shaten J., Stern M. P., Smith G. D., and Kuller L., Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men, American Journal of Epidemiology. (1996) 143, no. 9, 889–897, 2-s2.0-0029874336.
- 18 Dockery F., Bulpitt C. J., Agarwal S., Donaldson M., and Rajkumar C., Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia, Clinical Science. (2003) 104, no. 2, 195–201, 2-s2.0-0037326906, https://doi.org/10.1042/CS20020209.
- 19 Oh J.-Y., Barrett-Connor E., Wedick N. M., and Wingard D. L., Endogenous sex hormones and the development of type 2 diabetes in older men and women: the rancho bernardo study, Diabetes Care. (2002) 25, no. 1, 55–60, 2-s2.0-0036357643, https://doi.org/10.2337/diacare.25.1.55.
- 20 Smith M. R., Lee H., and Nathan D. M., Insulin sensitivity during combined androgen blockade for prostate cancer, Journal of Clinical Endocrinology and Metabolism. (2006) 91, no. 4, 1305–1308, 2-s2.0-33646029746, https://doi.org/10.1210/jc.2005-2507.
- 21
Smith J. C.,
Bennett S.,
Evans L. M.,
Kynaston H. G.,
Parmar M.,
Mason M. D.,
Cockcroft J. R.,
Scanlon M. F., and
Davies J. S., The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer, Journal of Clinical Endocrinology and Metabolism. (2001) 86, no. 9, 4261–4267, 2-s2.0-0034847215, https://doi.org/10.1210/jc.86.9.4261.
10.1210/jcem.86.9.7851 Google Scholar
- 22 Higano C. S., Ellis W., Russell K., and Lange P. H., Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study, Urology. (1996) 48, no. 5, 800–804, 2-s2.0-0030297953, https://doi.org/10.1016/S0090-4295(96)00381-0.
- 23 Braga-Basaria M., Dobs A. S., Muller D. C., Carducci M. A., John M., Egan J., and Basaria S., Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy, Journal of Clinical Oncology. (2006) 24, no. 24, 3979–3983, 2-s2.0-33748474608, https://doi.org/10.1200/JCO.2006.05.9741.
- 24 De Gonzalez A. B., Hartge P., Cerhan J. R., Flint A. J., Hannan L., MacInnis R. J., Moore S. C., Tobias G. S., Anton-Culver H., Freeman L. B., Beeson W. L., Clipp S. L., English D. R., Folsom A. R., Freedman D. M., Giles G., Hakansson N., Henderson K. D., Hoffman-Bolton J., Hoppin J. A., Koenig K. L., Lee I.-M., Linet M. S., Park Y., Pocobelli G., Schatzkin A., Sesso H. D., Weiderpass E., Willcox B. J., Wolk A., Zeleniuch-Jacquotte A., Willett W. C., and Thun M. J., Body-mass index and mortality among 1.46 million white adults, The New England Journal of Medicine. (2010) 363, no. 23, 2211–2219, 2-s2.0-78649747039, https://doi.org/10.1056/NEJMoa1000367.
- 25 Wilcoxon F., Individual comparisons by ranking methods, Biometrics Bulletin. (1945) 1, no. 6, 80–83, https://doi.org/10.2307/3001968.
- 26 Mann H. B. and Whitney D. R., On a test of whether one of two random variables is stochastically larger than the other, The Annals of Mathematical Statistics. (1947) 18, no. 1, 50–60, https://doi.org/10.1214/aoms/1177730491.
- 27 Mantel N. and Haenszel W., Statistical aspects of the analysis of data from retrospective studies of disease, The Challenge of Epidemiology: Issues and Selected Readings. (2004) 1, no. 1, 533–553.
- 28 Cochran W. G., Some methods for strengthening the common χ2 tests, Biometrics. (1954) 10, no. 4, 417–451, https://doi.org/10.2307/3001616.
- 29 Edge S. B. and Compton C. C., The american joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM, Annals of Surgical Oncology. (2010) 17, no. 6, 1471–1474, 2-s2.0-77954818058, https://doi.org/10.1245/s10434-010-0985-4.
- 30 Hilbe J. M., Logistic Regression Models, 2009, CRC Press, Boca Raton, Fla, USA.
- 31
Fisher R. A., On the interpretation of χ2 from contingency tables, and the calculation of P, Journal of the Royal Statistical Society. (1922) 85, no. 1, 87–94, https://doi.org/10.2307/2340521.
10.1111/j.2397-2335.1922.tb00768.x Google Scholar
- 32 Adams K. F., Schatzkin A., Harris T. B., Kipnis V., Mouw T., Ballard-Barbash R., Hollenbeck A., and Leitzmann M. F., Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old, The New England Journal of Medicine. (2006) 355, no. 8, 763–778, 2-s2.0-33747870163, https://doi.org/10.1056/NEJMoa055643.
- 33 Calle E. E., Thun M. J., Petrelli J. M., Rodriguez C., and HeathC. W.Jr., Body-mass index and mortality in a prospective cohort of U.S. adults, The New England Journal of Medicine. (1999) 341, no. 15, 1097–1105, 2-s2.0-0033533859, https://doi.org/10.1056/NEJM199910073411501.
- 34 Wilson P. W., D′Agostino R. B., Sullivan L., Parise H., and Kannel W. B., Overweight and obesity as determinants of cardiovascular risk: the Framingham experience, Archives of Internal Medicine. (2002) 162, no. 16, 1867–1872.
- 35 Van Gaal L. F., Mertens I. L., and De Block C. E., Mechanisms linking obesity with cardiovascular disease, Nature. (2006) 444, no. 7121, 875–880, 2-s2.0-33845914986, https://doi.org/10.1038/nature05487.
- 36 Rosengren A., Wedel H., and Wilhelmsen L., Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality, European Heart Journal. (1999) 20, no. 4, 269–277, 2-s2.0-0033001612, https://doi.org/10.1053/euhj.1998.1235.
- 37 Chan J. M., Rimm E. B., Colditz G. A., Stampfer M. J., and Willett W. C., Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men, Diabetes Care. (1994) 17, no. 9, 961–969, 2-s2.0-0027966932.
- 38 Lazar M. A., How obesity causes diabetes: not a tall tale, Science. (2005) 307, no. 5708, 373–375, 2-s2.0-12344266697, https://doi.org/10.1126/science.1104342.
- 39 Meng M. V., Elkin E. P., Latini D. M., DuChane J., and Carroll P. R., Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE), The Journal of Urology. (2005) 173, no. 5, 1557–1561, 2-s2.0-17244382914, https://doi.org/10.1097/01.ju.0000154610.81916.81.
- 40 Kucway R., Vicini F., Huang R., Stromberg J., Gonzalez J., and Martinez A., Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy, The Journal of Urology. (2002) 167, no. 6, 2443–2447, 2-s2.0-0036090487.
- 41 Potters L., Torre T., Ashley R., and Leibel S., Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy, Journal of Clinical Oncology. (2000) 18, no. 6, 1187–1192, 2-s2.0-0034061841.
- 42 Mohler J. L., NCCN clinical practice guidelines in oncology on prostate cancer, Journal of the National Comprehensive Cancer Network. (2010) 8, no. 2, 2-s2.0-77649170747.
- 43 Zumsteg Z. S., Spratt D. E., Pei I., Zhang Z., Yamada Y., Kollmeier M. et al., A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy, European Urology. (2013) 64, no. 6, 895–902, https://doi.org/10.1016/j.eururo.2013.03.033.
- 44 D′Amico A. V., Chen M.-H., Renshaw A. A., Loffredo M., and Kantoff P. W., Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial, Journal of the American Medical Association. (2008) 299, no. 3, 289–295, 2-s2.0-38349164176, https://doi.org/10.1001/jama.299.3.289.
- 45 Sanda M. G., Dunn R. L., Michalski J., Sandler H. M., Northouse L., Hembroff L., Lin X., Greenfield T. K., Litwin M. S., Saigal C. S., Mahadevan A., Klein E., Kibel A., Pisters L. L., Kuban D., Kaplan I., Wood D., Ciezki J., Shah N., and Wei J. T., Quality of life and satisfaction with outcome among prostate-cancer survivors, The New England Journal of Medicine. (2008) 358, no. 12, 1250–1261, 2-s2.0-40949147326, https://doi.org/10.1056/NEJMoa074311.
- 46 Berg C. D., Andriole G. L., Crawford E. D., Grubb R. L., Buys S. S., Chia D., Church T. R., Fouad M. N., Gelmann E. P., Kvale P. A., Reding D. J., Weissfeld J. L., Yokochi L. A., O′Brien B., Clapp J. D., Rathmell J. M., Riley T. L., Hayes R. B., Kramer B. S., Izmirlian G., Miller A. B., Pinsky P. F., Prorok P. C., and Gohagan J. K., Mortality results from a randomized prostate-cancer screening trial, The New England Journal of Medicine. (2009) 360, no. 13, 1310–1319, 2-s2.0-63249122661, https://doi.org/10.1056/NEJMoa0810696.
- 47 Schröder F. H., Hugosson J., Roobol M. J., Tammela T. L. J., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Määpttänen A. B., Bangma C. H., Aus G., Villers A., Rebillard X., Van Kwast T. D., Blijenberg B. G., Moss S. M., De Koning H. J., and Auvinen A., Screening and prostate-cancer mortality in a randomized european study, The New England Journal of Medicine. (2009) 360, no. 13, 1320–1328, 2-s2.0-63249118690, https://doi.org/10.1056/NEJMoa0810084.
- 48 Hugosson J., Carlsson S., Aus G., Bergdahl S., Khatami A., Lodding P., Pihl C.-G., Stranne J., Holmberg E., and Lilja H., Mortality results from the Göteborg randomised population-based prostate-cancer screening trial, The Lancet Oncology. (2010) 11, no. 8, 725–732, 2-s2.0-77955279420, https://doi.org/10.1016/S1470-2045(10)70146-7.
